BRISTOL-MYERS SQUIBB COMPANY Net Income (Loss) Available to Common Stockholders, Diluted
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Net Income (Loss) Available to Common Stockholders, Diluted of $3.70 billion for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-17.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2012-02-17
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, diluted for fiscal 2011 was $3.70B, a 19.77% increase from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, diluted for fiscal 2010 was $3.09B, a 70.72% decline from fiscal 2009.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, diluted for fiscal 2009 was $10.55B.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|
| 2011-12-31 | $3.70B 10-K · filed 2012-02-17 |
| 2010-12-31 | $3.09B 10-K · filed 2012-02-17 |
| 2009-12-31 | $10.55B 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |